Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23521838 | 1.00 | KDM4E (0.45) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL23521842 | 1.00 | KDM4E (0.45) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL29662251 | 1.00 | KDM4E (0.45) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL23522145 | 0.89 | KDM4E (0.51) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL30418860 | 0.89 | KDM4E (0.51) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL23522147 | 0.89 | KDM4E (0.51) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL23522224 | 0.86 | ALDH1A1 (0.43) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL23522223 | 0.86 | ALDH1A1 (0.43) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL23522203 | 0.86 | KDM4E (0.43) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL21731364 | 0.86 | KDM4E (0.46) | KDM4EMAPTRAB9AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630511-B2 | Benzamide derivative, preparation method therefor, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2026-05-19 | — | — | US | disclosed |
| US-20240246948-A1 | BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | HK INNO.N CORPORATION (KR) | 2024-07-25 | — | — | US | disclosed |
| US-11976059-B2 | Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-05-07 | — | — | US | disclosed |
| EP-4342882-A1 | BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | HK inno.N Corporation (KR) | 2024-03-27 | — | — | EP | disclosed |
| EP-3838898-B1 | ISOINDOLIN-1-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS AN EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022245061-A1 | BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 에이치케이이노엔 주식회사 | 2022-11-24 | — | — | WO | disclosed |
| US-20220281817-A1 | BENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-4005572-A1 | BENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2022-06-01 | — | — | EP | disclosed |
| US-20210332029-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-10-28 | — | — | US | disclosed |
| EP-3838898-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | Korea Research Institute of Chemical Technology (KR) | 2021-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246948-A1 | BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT | EGFR, ERBB2, TP53 | KDM4E 1627/4885MAPT 4300/4885RAB9A 3091/4885 |
| US-20210332029-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | EGFR, TP53, BRCA1 | KDM4E 4462/4885MAPT 2651/4885RAB9A 3553/4885 |
| US-20220281817-A1 | BENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | EGFR, WEE1, WEE2 | KDM4E 2110/4885MAPT 4157/4885RAB9A 3372/4885 |
| US-12630511-B2 | Benzamide derivative, preparation method therefor, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer | EGFR, ERBB2, KRAS | KDM4E 3236/4885MAPT 4195/4885RAB9A 1643/4885 |
| US-11976059-B2 | Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer | EGFR, TP53, BRCA1 | KDM4E 4462/4885MAPT 2651/4885RAB9A 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.